Fuji Receives Patent on Astaxanthin, Inflammation

MOUNT LAUREL, N.J.—Fuji Chemical Industry Co. Ltd., the parent company of Fuji Health Science Inc., was granted U.S. Patent No. 7,078,040, covering the ability of astaxanthin to inhibit the expression of inflammatory cytokines and chemokines. Fuji, the producer of AstaREAL® astaxanthin, holds additional patents for astaxanthin in areas including muscle endurance, immunomodulation, gastric health and fertility; its pending patents include eye fatigue, wrinkle reduction, weight loss, diabetic nephropathy and dyspepsia.

“Our intellectual property is an indicator of Fuji’s dedication to support the research into the benefits of astaxanthin,” said Charles DePrince, president of Fuji Health Science (www.fujihealthscience.com). “This support continues aggressively with our newest research involving the areas contributing to metabolic syndrome.”